



30pm-13:20pm (GMT+9

Chairperson 1

Dr. Ann-Lii Cheng

National Taiwan University College of Medicine, Taiwan



Chairperson 2

Dr. Ju Hyun Shim

Asan Medical Center, Korea



Speaker 1 | 25min (12:30 -12:55)

Deep dive into the Lenvatinib From MOA to the clinical outcome Dr. Ying-Chun Shen

National Taiwan University Cancer Center, Taiwan



Speaker 2 | 25min (12:55 -13:20)

The evoloving role of multi kinase inhibitor therapy for HCC: Focusing on Lenvatinib

Dr. Pil Soo Sung

The Catholic Univ. of Korea Seoul St. Mary's Hospital, Korea



